Based on the National Institute on Aging—Alzheimer’s Association (NIA-AA) Research Framework for the biological definition of AD [18], incorporating biomarker data into cognitive classifications in future studies will allow for establishing the utility of the DCR for identifying CU, MCI, and dementia groups who are amyloid- and/or tau-positive or negative. The gene discussed is MAPT; the disease is Alzheimer disease.